Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

Authors and Affiliations

1. Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany

   Othman Al-Sawaf, Can Zhang, Sandra Robrecht, Anna Maria Fink, Karl-Anton Kreuzer, Christian P. Pallasch, Lukas P. Frenzel, Barbara Eichhorst, Michael Hallek & Kirsten Fischer

2. Cancer Institute, University College London, London, UK

   Othman Al-Sawaf

3. Francis Crick Institute, London, UK

   Othman Al-Sawaf

4. Genentech Inc., South San Francisco, CA, USA

   Hyun Yong Jin, Yoonha Choi, Sandhya Balasubramanian, Joseph N. Paulson & Yanwen Jiang

5. Roche Products Ltd, Welwyn Garden City, UK

   Alex Kotak

6. Hoffmann-la Roche, Mississauga, ON, Canada

   Yi Meng Chang

7. Department III of Internal Medicine, Ulm University, Ulm, Germany

   Eugen Tausch, Christof Schneider & Stephan Stilgenbauer

8. Department II of Internal Medicine, University of Schleswig Holstein, Kiel, Germany

   Matthias Ritgen

9. AbbVie Inc., North Chicago, IL, USA

   Brenda Chyla

10. Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, University of Cologne, Cologne, Germany

    Martin Peifer

Corresponding authors

Correspondence to Othman Al-Sawaf, Michael Hallek or Kirsten Fischer.

The original article can be found online at https://doi.org/10.1038/s41467-023-37648-w.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions